Filling in at the Helm, Mollica Seeks New Captain to Steer Accelrys Toward the $200M Mark | GenomeWeb

Despite the downturn in the bioinformatics sector this year, Joseph Mollica is bullish about his company’s chances for growth.

“I’d like to see the market grow a little bit more, and we’re impacted like everyone by the general economy and overall IT spending in corporate America, but I think the results we’ve had at Accelrys show that we’re still growing the business,” the CEO of Pharmacopeia, Accelrys’ parent company, told BioInform last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.